SCHOTT Pharma launched its first 5.5 mL prefillable staked-needle glass syringe, expanding its syriQ BioPure platform to support self-administered biologics and home care. Designed for therapies in immunology, oncology, and CNS disorders, the syringe combines ultra-low tungsten levels with robust device compatibility. Including integration with Ypsomed’s YpsoMate 5.5 mL autoinjector and Datwyler’s latest plunger, for the safe, stable delivery of sensitive biologics.

The company aims to address the growing need for large-volume drug delivery systems as pharma companies move from intravenous to subcutaneous home administration. 

SCHOTT Pharma will be showcasing the new syringe and its large-volume portfolio at CPHI Frankfurt, highlighting how advanced glass technologies are enabling next-generation drug containment and delivery solutions.

“This portfolio expansion marks a significant step for SCHOTT Pharma in advancing the trend of self-administering substantial drug doses subcutaneously at home. With device-compatible large-volume options across all our product ranges and collaborations with leading device manufacturers, we provide pharma companies with solutions to efficiently scale homecare offerings and expedite their market entry,” said Andreas Reisse, CEO of SCHOTT Pharma.